A rating of 82 puts Mirati Therapeutics Inc (MRTX) near the top of the Biotechnology industry according to InvestorsObserver. Mirati Therapeutics Inc's score of 82 means it scores higher than 82% of stocks in the industry. Mirati Therapeutics Inc also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 35 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Mirati Therapeutics Inc (MRTX) stock is lower by -0.6% while the S&P 500 is up 0.34% as of 11:44 AM on Wednesday, Dec 30. MRTX is down -$1.32 from the previous closing price of $220.94 on volume of 154,477 shares. Over the past year the S&P 500 has gained 15.75% while MRTX is up 70.43%. MRTX lost -$7.70 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Mirati Therapeutics Inc (MRTX) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the rest here:
Is Mirati Therapeutics Inc (MRTX) the Top Pick in the Biotechnology Industry? - InvestorsObserver